Pevonedistat Plus Azacitidine Versus Single-Agent Azacitidine as First-Line Treatment for Participants With Higher-Risk Myelodysplastic Syndromes (HR MDS), Chronic Myelomonocytic Leukemia (CMML), or Low-Blast Acute Myelogenous Leukemia (AML)
A phase 3 trial of Azacitidine and Pevonedistat in Leukaemia, run by Takeda, completed.
Overview
Pevonedistat Plus Azacitidine Versus Single-Agent Azacitidine as First-Line Treatment for Participants With Higher-Risk Myelodysplastic Syndromes (HR MDS), Chronic Myelomonocytic Leukemia (CMML), or Low-Blast Acute Myelogenous Leukemia (AML) is a phase 3 interventional study registered as NCT03268954 by Takeda, with 454 participants recorded, started 2017-11-28 and reaching its primary completion in 2021-05-28. Interventions recorded: Azacitidine, Pevonedistat. Conditions recorded: Myelodysplastic Syndrome, Leukemia, Myelomonocytic, Chronic, Leukemia, Myeloid, Acute.
Linked to the drug Pevonedistat because the registry names it among its interventions and Leukaemia among its conditions. Registry record only: no result has been read by an editor.
Similar pages
not linked directly; found by shared links- TrialStudy to Compare Azacitidine Plus Pevonedistat Versus Azacitidine in Patients With Acute Myeloid Leukemia Not Eligible for Standard Chemotherapy
Shares Pevonedistat, Leukaemia (all types), Azacitidine and the tag pipeline.
- TrialContinuation Study of B1371019(NCT03416179) and B1371012(NCT02367456) Evaluating Azacitidine With Or Without Glasdegib In Patients With Previously Untreated AML, MDS or CMML
Shares Leukaemia (all types), Azacitidine and the tag pipeline.
- TrialStudy of Azacitidine，Venetoclax，and Flumatinib in Newly Diagnosed Ph-positive Acute Leukemia and CML-AP/BP Patients
Shares Leukaemia (all types), Azacitidine and the tag pipeline.
- TrialA Study Evaluating Intensive Chemotherapy With or Without Glasdegib or Azacitidine With or Without Glasdegib In Patients With Previously Untreated Acute Myeloid Leukemia
Shares Leukaemia (all types), Azacitidine and the tag pipeline.
- TrialA Study of TAK-188 in Adults With Advanced or Spreading Solid Tumors
Shares Takeda and the tag pipeline.
- TrialA Study of TAK-505 in Adults With Solid Tumors
Shares Takeda and the tag pipeline.
- TrialA Study of Gammagard Liquid (Immune Globulin Infusion, 10%) to Prevent Infections in Adults With Multiple Myeloma
Shares Takeda and the tag pipeline.
- TrialA Study of TAK-007 in Adults With Relapsed or Refractory (r/r) B-cell Non-Hodgkin Lymphoma (NHL)
Shares Takeda and the tag pipeline.